Contact the Antimicrobial Management Team if Physician insists on using this agent for treatment of COVID-19 after explanation/discussion with him/her.

IVIG Prioritization Policy

Starting June 1st, 2020, Gamunex Product Selection Change will go into place. 

For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents 

Pediatrics: Gamunex-C is classified as the preferred formulary workhorse agent (updated 6/22/2022)

Gammagard will be the primary alternative product and restricted to situations where Gamunex-C is unavailable, or the patient has had a reaction to Gamunex-C that cannot be mitigated with symptom-targeting medications/pre-medications and/or slowing of infusion rate. For cases involving patients with an order for another specific IVIG product, each patient will be evaluated on a case by case basis for usage and financial considerations (updated 2/15/2024).

Dosing:

To calculate the ACTUAL DOSE: Use ideal body weight (IBW*) on adult inpatient orders
Exceptions:
*Obese patients (> 130% of IBW)---> Use Adjusted Body Weight (AdjBW): AdjBW = IBW + 0.5 (Total Body Weight - IBW)
*If patient's total body weight is less than IBW, use total body weight.

To calculate the INFUSION RATES: Use total body weight (TBW) on all adult inpatient orders. Round the infusion rate to the nearest mL/hr. Enter the calculated starting rate into the rate field in Cerner.

Dose Rounding: To the nearest 5 g for patients 18 years and over (Approved P&T - February 26, 2013)

Updated: February 26, 2013 (Dose Rounding), and March 27, 2018 (IBW/AdjBW Dosing), and June 1st 2020 (Gamunex Verification Change), and 27th, 2021 (COVID treatment), March 7, 2022 (Gammagard and Gamunex), June 2022 (Pediatrics: Gamunex), February 12, 2024 (Gamunex)

• Micromedex
• UpToDate
• Lippincott Advisor